Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionStandard Life Aberdeen plc
Latest Disclosed Ownership138,331 shares
Latest Disclosed Value $ 45,769,578
Standard Life Aberdeen plc reports 4.13% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On April 29, 2026 - Standard Life Aberdeen plc filed a 13F-HR form disclosing ownership of 138,331 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $39,521,167 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 132,846 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 4.13% during the quarter. The current value of the position is $36,035,226 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-29 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 138,331 5,485 4.13 45,770 -13.36 0.0401
2026-01-16 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 132,846 -24,550 -15.60 52,826 -26.34 0.0818
2025-11-07 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 157,396 -61,228 -28.01 71,720 1.93 0.1134
2025-07-24 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 218,624 3,239 1.50 70,364 23.33 0.1197
2025-05-13 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 215,385 24,544 12.86 57,054 26.22 0.1113
2025-01-24 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 190,841 -9,228 -4.61 45,203 -17.81 0.0849
2024-10-25 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 200,069 91 0.05 54,998 13.18 0.1008
2024-08-09 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 199,978 -19,297 -8.80 48,595 48.29 0.0932
2024-05-09 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 219,275 -13,441 -5.78 32,771 -26.43 0.0643
2024-01-31 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 232,716 209,691 910.71 44,544 992.57 0.0966
2023-11-07 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,025 -559 -2.37 4,078 -8.98 0.0104
2024-06-20 2023-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 23,584 130 0.55 4,480 -4.66 0.0104
2023-08-04 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,584 130 4,480 0.0104
2024-06-20 2023-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 23,454 10,330 78.71 4,698 50.67 0.0118
2023-04-28 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,454 10,330 4,698 0.0118
2024-06-20 2022-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 13,124 915 7.49 3,119 27.58 0.0085
2023-02-10 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,124 915 3,119 0.0085
2022-11-10 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,209 1,408 13.04 2,444 55.17 0.0073
2022-08-05 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,801 -222 -2.01 1,575 -12.79 0.0050
2022-05-04 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,023 -144 -1.29 1,806 -4.60 0.0046
2022-02-10 2021-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 11,167 382 3.54 1,893 -7.02 0.0042
2022-02-08 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,167 382 1,893 0.0014
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,785 683 6.76 2,036 18.93 0.0046
2021-08-10 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,102 -2,043 -16.82 1,712 -0.17 0.0037
2021-05-06 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,145 260 2.19 1,715 10.93 0.0039
2021-02-10 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,885 159 1.36 1,546 -9.48 0.0038
2020-10-21 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,726 -3,016 -20.46 1,708 -21.76 0.0046
2020-08-10 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,742 363 2.52 2,183 39.49 0.0059
2020-05-13 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,379 -142 -0.98 1,565 -6.46 0.0050
2020-02-18 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,521 1,126 8.41 1,673 55.34 0.0040
2019-11-13 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,395 533 4.14 1,077 15.43 0.0027
2019-08-13 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,862 1,276 11.01 933 -13.85 0.0021
2019-05-14 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,586 6,793 141.73 1,083 229.18 0.0023
2019-02-12 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,793 -50 -1.03 329 -22.41 0.0008
2018-11-20 2018-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 4,843 -110 -2.22 424 -13.11 0.0008
2018-11-13 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,843 -110 424
2018-08-09 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,953 4,953 488 0.0009
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.